Related Experiment Video
Updated: Jun 26, 2025
07:17
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
10.5K
GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer
Casper W F van Eijck1, Francisco X Real2, Núria Malats3
1Department of Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Madrid, Spain.
Cell Reports. Medicine
|May 11, 2024
Summary
High GATA6 expression in pancreatic ductal adenocarcinoma (PDAC) predicts better survival and a classical phenotype. GATA6 also influences the tumor immune microenvironment, offering potential for novel combination therapies.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- GATA6 is a transcription factor implicated in various cancers.
- Previous retrospective studies suggest GATA6 immunohistochemistry (IHC) expression correlates with survival in pancreatic ductal adenocarcinoma (PDAC).
- Prospective validation of GATA6's prognostic role in PDAC is needed.
Purpose of the Study:
- To prospectively evaluate GATA6 IHC as a prognostic marker in treatment-naive resected PDAC.
- To investigate the impact of neoadjuvant therapy on GATA6's prognostic significance.
- To explore the immunomodulatory role of GATA6 in PDAC.
Main Methods:
- Prospective cohort study of patients with resected PDAC.
- GATA6 immunohistochemistry (IHC) staining and analysis.
- Correlation of GATA6 expression with survival outcomes and PDAC phenotype.
- Analysis of the tumor immune microenvironment based on GATA6 expression levels.
Main Results:
- High GATA6 expression was associated with improved survival and the classical PDAC phenotype in treatment-naive patients.
- GATA6's prognostic significance was reduced after gemcitabine-based neoadjuvant chemoradiotherapy compared to upfront surgery.
- Distinct immunological landscapes were observed in PDAC tumors with varying GATA6 expression.
- High GATA6 tumors exhibited reduced immunosuppressive cells (regulatory T cells, M2 macrophages) and increased immune-stimulating cells (antigen-presenting, activated T cells).
Conclusions:
- GATA6 is a valuable prognostic marker for classical PDAC in treatment-naive patients.
- Neoadjuvant therapy may diminish the prognostic utility of GATA6.
- GATA6 influences the PDAC immune microenvironment, suggesting potential for immune-based therapies.
- Relying solely on GATA6 for molecular subtyping in clinical trials may be insufficient.
